Study design, patient eligibility and treatment This was a phase 1, first-in-human, open-label, nonrandomized, dose-escalation ...
Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global ...
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and ...
IHME Pathogen Core Group. Global burden associated with 85 pathogens in 2019: a systematic analysis ...
Fenis, A., Demaria, O., Gauthier, L., Vivier, E. & Narni-Mancinelli, E. New immune cell engagers ...
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and ...
The U.S. Department of Health and Human Services (HHS) announced plans to study the potential ...
In a recent study published in Nature, Grippin and colleagues showed that SARS-CoV-2 mRNA vaccines ...
Construction and characterization of the bispecific cell engager MSLN×CD16A To construct the bispecific cell engager ...
Cell culture C57BL/6 mice derived from the melanoma cell line B16F10, the colon cancer cell ...